Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $426000.0.

  • Macrogenics' Capital Expenditures fell 2804.05% to $426000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 3820.83%. This contributed to the annual value of $3.7 million for FY2024, which is 11009.07% up from last year.
  • Per Macrogenics' latest filing, its Capital Expenditures stood at $426000.0 for Q3 2025, which was down 2804.05% from $715000.0 recorded in Q2 2025.
  • In the past 5 years, Macrogenics' Capital Expenditures ranged from a high of $2.1 million in Q3 2021 and a low of $286000.0 during Q2 2023
  • Moreover, its 5-year median value for Capital Expenditures was $626000.0 (2021), whereas its average is $892842.1.
  • As far as peak fluctuations go, Macrogenics' Capital Expenditures surged by 32745.49% in 2021, and later crashed by 7462.9% in 2023.
  • Quarter analysis of 5 years shows Macrogenics' Capital Expenditures stood at $1.4 million in 2021, then crashed by 71.42% to $393000.0 in 2022, then soared by 57.76% to $620000.0 in 2023, then changed by 0.0% to $620000.0 in 2024, then crashed by 31.29% to $426000.0 in 2025.
  • Its Capital Expenditures stands at $426000.0 for Q3 2025, versus $715000.0 for Q2 2025 and $529000.0 for Q1 2025.